KETOROLAC [TORADOL]

DRUG CLASSIFICATION	Carboxylic Acid Derivative Prostaglandin G/H Synthase 1 & 2 Inhibitor Nonsteroidal Anti-Inflammatory Drug Nonopioid Analgesic Agent Antipyretic Agent
MECHANISM OF ACTION	Inhibits key pathways in prostaglandin synthesis by reversibly and non-selectively inhibiting COX-1 and COX-2 enzymes, resulting in decreased formation of prostaglandin precursors, achieving analgesia and inflammation reduction effects.
CLINICAL INDICATIONS	Moderate-to-Severe Pain
STANDARD CONTRAINDICATIONS	Hypersensitivity to Ketorolac, NSAID's, or Other Relative Components Pediatric Patient Population (Age < 6 Months) Known or Suspected Gastrointestinal Bleeding Disorders / Gastrointestinal Peptic Ulcers Known or Suspected Concomitant Use of Aspirin, other NSAIDs, Probenecid, or Pentoxifylline Known or Suspected Cerebrovascular Bleeding / Hemorrhagic Diathesis / Incomplete Hemostasis / High Risk of Bleeding Known or Suspected Renal Insufficiency / Renal Disease / Renal Transplant / Risk of Renal Failure Due to Volume Depletion
POTENTIAL ADVERSE EFFECTS	Hepatotoxicity **/** Nephrotoxicity **/** Skin Rash **/** Anemia **/** Bleeding **/** Dizziness **/** Abdominal Pain **/** Fluid Retention **/** Hypertension
GENERAL RISKS & PRECAUTION	**1)** Use with caution for patients with known or suspected risks of cardiovascular thrombotic events such as MI or stroke. **2)** Use may increase risk of hyperkalemia in patients with diabetes, renal disease, or those who are ≥ 65 years of age. **3)** Use caution for patients that have platelet disorders, bleeding disorders, and/or similar prescribed medication.
PROTOCOL INDEX	Pain Control (UP-11)

MEDICATION ADMINISTRATION

ADULT	PEDIATRIC
Moderate-to-Severe Pain Control 15 mg [IV/IO]; **or** 30 mg [IM] (Maximum Dose: 30 mg)	**Moderate-to-Severe Pain Control** 0.5 mg / kg [IV/IO/IM] (Maximum Dose: 30 mg)